BUFFALO, N.Y., June 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, Inc. announced today, that the FDA has allowed its Investigational New Drug (IND) application for KX02, Kinex's dual src/pretubulin ...
The lead products include an oral formulation of paclitaxel, which is already in Phase II clinical trials in Korea, and an oral formulation of irinotecan, which has just completed Phase I clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results